Introduction
Cell type | Origin | Biomarker | Regulatory Mechanism | Immunophenotype | Function Features |
---|---|---|---|---|---|
TAM | Monocytic precursors in bone marrow, spleen and embryo | M1: F4/80+CD11b+CD86+ M2: F4/80+CD11b+CD206+ Embryo-specific: CX3CR1highCD11alow CD49dlow | (a) Differentiation: CSF-1, TGF-β, VEGF, platelet-derived growth factor (b) Polarization: M1 (IFN-γ, lipopolysaccharide); M2 (IL-4, IL-13) (c) Proliferation: GM-CSF and adenosine Embryo-specific: (a) AngII-AGTR1A increase HSCs retention (b) EMPs buds from the yolk sac endothelium (c) Colonize the embryonic tissue or liver (d) Differentiate from the early or later wave | M1: iNOS, ROS, IL-1β, TNF-α, IL-12, IFN-γ M2: ARG1, IL-10, TGF-β, VEGF, MMP | M1: (a) Kill tumor cells (b) Activate NK cells and cytotoxic T cells M2: (a) Inhibit T cells and NK cells activition (b) Induce angiogenesis (c) Promote tumor growth and invasion (d) Recruit Tregs into TME Embryo-specific: Pro-fibrotic |
MDSC | M-MDSC: Monocytic precursors in bone marrow and spleen PMN-MDSC: Granulocytic precursors, monocytic-like precursors in Bone marrow and spleen | M-MDSC: CD11b+CD14+HLA-DR–/loCD15− (human), CD11b+Ly6G−Ly6Chi (mouse) PMN-MDSC: CD11b+CD14−CD15+/CD66b+ (human), CD11b+Ly6G+Ly6Clo (mouse) Splenic MDSC: PMN-like cell | (a) Differentiation: IL-1β, IL-6, S100A8-9, IFN-γ, IL-4, IL-13, IL-10 (b) Accumulation and expansion: IL-6, IL-10, TGF-β Splenic MDSC-specific: (a) Recruit specific HSPCs via CCL2/CCR2 (b) Endogenous GM-CSF signals and local education by the splenic stroma | M-MDSC: iNOS, ARG1, IL-10, TGF-β PMN-MDSC: ROS, PGE2, IDO, ARG1 | (a) Reduce the anti-tumor activity of T cells (b) Inhibit NK cells, macrophages, dendritic cells function (c) Induce Tregs |
TAN | Granulocytic precursors in Bone marrow | CD15+CD16+CD66b+CD14− (human), CD11b+Ly6G+ (mouse) | Polarization: N1 (type 1 interferon); N2 (TGF-β) | CCL2, CCL17 | N1: Kill tumor cells directly Activate dendritic cells, CD4+ T cells, etc N2: Inhibit tumor cell apoptosis Promote angiogenesis Inhibit CD8+ T cells function Promote tumor invasion and metastasis Recruite macrophages and Tregs into TME |
TADC | Dendritic cell precursors in bone marrow | pDC: BDCA-2+BDCA-4+IL-3Ra+ CD11c− (human), CD45R+CD317+Siglec-H+ CD11clow (mouse) cDC1: BDCA3+CD141high cDC2: BDCA1+CD1c+ moDC: Indistinguishable from cDC2 | Development and maintenance of phenotype: (a) pDCs: E protein transcription factor E2-2 (b) cDCs: E protein antagonist Id2 | pDC: IDO, ICOSL, PD-L1, granulosase B cDC1: TNF-α, IL-6, IL-8, IL-12, CXCL9, CXCL10 cDC2: IL-1β, IL-6, IL-12, IL-23 moDC: NOS2, CD40 L, TNF | pDC: Inhibit CD8+ T cells function Induce Tregs cDC1: Cross-presentation Polarize and activate CD4+ T cells Activate NK cell Recruit CD8+ T cells into TME cDC2: Activate CD4+ T cells moDC: Promote CD8+ T cell to kill tumor cells |
EDMC | CD45+ EPCs in extramedullary organ (especially spleen) | CD235a+CD71+CD11b+CD33+HLA-DR− (human), Ter119+CD71+CD11b+Gr1+ (mouse) | (a) Tumors block the default erythrocyte differentiation pathway of CD45+ EPCs (b) GM-CSF… mediate erythrocyte-myeloid trans-differentiation | High level of PD-L1, Arg-1, iNos, ROS, et al | Strong ability to inhibit CD8+T cell proliferation and IFN-γ production, promote tumor growth and invasion |
B-MF | Pre-B in local tumor | CD19+CD79a+IgM+ TAM | (a) Tumors mobilize BM pre-B accumulation in the spleen (b) Acquisition of myeloid characteristics: Tumors decrease PAX5 levels using M-CSF | High level of PD-L2, B7-H3, Marco, TGF-β, et al | (a) Inhibit CD4+ T cell and induce Treg (b) Unique metabolic and inflammatory functions (c) Strong phagocytic ability |
Origin of classical TAMCs
Tumor-trained myeloid-biased differentiation in BM
Tumor-associated macrophage (TAM)
M1-TAM and M2-TAM
Proliferating TAM in local tumors
MDSC
Tumor-associated neutrophil (TAN)
Tumor-associated dendritic cell (TADC)
Splenic HSPCs mediated tumor-promoting myelopoiesis
Tumor-induced erythroid precursor-differentiated myeloid cells
Tumor-induced B precursor cells differentiated macrophage-like cells
Embryo-derived TAM
Technologies used for studying heterogeneous TAMCs
TAMCs | Contents | Technologies |
---|---|---|
TAM | Origin | Ms4a3TdT, Ms4a3Cre, Ms4a3CreERT2 mouse models to specifically dissect monocyte-differentiation pathways |
Biomarkers | F4/80, CD11b, CD86, CD206, etc | |
Chemotaxis | Anti-CCL2 antibody, CCL5-KO mouse, etc., used to block TAM recruitment | |
Regulation | Anti-M-CSF antibody, anti-CSF-1R antibody, etc., used to interfere with TAM differentiation | |
Function | Liposomal clodronate, CD11b-DTR mouse, etc., used to verify the effect of TAM clearance | |
MDSC | Origin | Splenectomy is performed to determine the origin of splenic MDSC |
Biomarkers | CD11b, CD14, CD15, CD66b, HLA-DR (human) and CD11b, Ly6G, Ly6C (mouse), etc | |
Chemotaxis | CXCR2 blockade, CXCR4 blockade, etc., used to inhibit MDSC recruitment | |
Regulation | GM-CSF overexpression cell line (e.g. B16-GM), anti-GM-CSF antibody, etc., used to explore the factors regulating MDSC differentiation | |
Function | (a) Anti-Gr-1 antibody, etc., used to consume MDSC (b) DR5 agonist, LXR agonist, etc., used to induce apoptosis of MDSC | |
TAN | Origin | Label by mNPPFC (mNP specifically bind to CD177) to follow TAN |
Biomarkers | CD15, CD16, CD66b, CD14, HLA-DR (human) and CD11b, Ly6G (mouse), etc | |
Chemotaxis | CXCR2 blockade, etc., used to inhibit TAN recruitment | |
Regulation | Anti-TGF-βantibody, anti-IFN-γantibody, etc., used to explore the regulation of TAN polarization | |
Function | (a) Clear by anti-Ly6G antibody (b) Induce by G-CSF | |
TADC | Origin | Zbtb46-GFP mouse to track TADC |
Biomarkers | BDCA-1, BDCA-2, BDCA-3, BDCA-4, CD141, CD1c, CD11c, IL-3Ra, CD45R, CD317, Siglec-H, etc | |
Chemotaxis | Anti-CCL5 antibody, anti-CXCL12 antibody, etc., used to block TADC recruitment | |
Regulation | Anti-TGF-β antibody, anti-TPO antibody, etc., used to explore the factors regulating TADC differentiation | |
Function | CD11c-DTR mouse, Zbtb46-2A-CreERT2 mouse, etc., used to conditionally remove TADC |
Therapeutic strategies based on TAMCs
Inhibiting tumor-promoting myelopoiesis
Anti-G-CSF and anti-GM-CSF antibody
Targeting EMH
EPO
Blocking the expansion and recruitment of TAMCs
Strategies | Class | Treatment | Conditions | With ICBs or not | Outcomes | Adverse effects |
---|---|---|---|---|---|---|
Blocking expansion and recruitment of TAMCs | CCR2 inhibitor | PF-04136309, MLN1202, BMS-813160, etc | Pancreatic ductal adenocarcinoma, melanoma, metastatic cancer, etc | Both monotherapy and synergistic ICBs are available | ORR was 16.7–49%. About 33% of patients had reduced metastasis markers. But some trials have been stopped for lack of clinical benefit | Fatigue and anemia were common. DLTs were present. Neutropenia may occur with concurrent chemotherapy |
VEGFR inhibitor | Axitinib, Cabozantinib, Pazopanib, etc | Renal cell carcinoma, breast cancer, small cell lung cancer, etc | Both monotherapy and synergistic ICBs are available | OS and PFS were significantly prolonged, and ORR was increased | The incidence rate of serious AEs was about 40%. The most common AE was diarrhea | |
CSF1R inhibitor | Cabiralizumab, PLX3397, ARRY-382, etc | Advanced solid tumor, melanoma, non-small cell lung cancer, etc | Mostly in collaboration with ICBs | The objective response rate was 0–16.7%. PFS did not prolong significantly | The incidence rate of serious AEs and DLTs was 0–54.5%. Gastrointestinal diseases were common | |
Mitigating the immunosuppressive ability of TAMCs | COX-2 inhibitor | Celecoxib, apricoxib, etc | Breast cancer, non-small cell lung cancer, etc | Collaboration with ICBs is rare | PFS did not significantly prolong or even shorten. There was no clinical benefit | The incidence rate of serious AEs was similar to that of placebo group |
PDE5 inhibitor | Tadalafil, Sildenafil, etc | Head and neck squamous cell carcinoma, prostatic neoplasms, etc | No | The activity of Arg-1 and iNOS was significantly decreased, reversing tumor specific immune suppression | No AEs are reported | |
TLR agonist | CMP-001, Imiquimod, SD-101, etc | Melanoma, head and neck cancer, breast cancer, etc | Mostly in collaboration with ICBs | ORR was 0–55.6%, and progressive disease accounted for 11.1–44.4%. MPR also showed a mix of good and bad outcomes | The incidence rate of serious AEs was 16.67–44.4%. Chills and fatigue were prominent | |
Direct depletion | VEGFR inhibitor | Sunitinib malate, ZD6474, Apatinib, etc | Renal cell carcinoma, bladder cancer, breast cancer, gastric cancer, etc | Both monotherapy and synergistic ICBs are available | PFS and OS were prolonged in most trials. Some studies have shown that MDSC mediated immunosuppression is reversed | The incidence rate of serious AEs was 6.67–40%. Leukocytes and platelets were often affected |
C-kit inhibitor | Imatinib, Masitinib, Dasatinib, Dovitinib, etc | Salivary gland neoplasm, non-small cell lung cancer, melanoma, thyroid cancer, etc | Collaboration with ICBs is rare | Clinical benefit was limited. PFS was prolonged in some trials, but the results of some trials were mainly progressive disease | The incidence rate of serious AEs was 2.44–65%. Among them, diarrhea, nausea and vomiting were easy to occur | |
Chemo therapy | Cisplatin, 5-FU, Carboplatin, Paclitaxel, Doxorubicin, etc | Esophageal neoplasms, breast cancer, non-small cell lung cancer, ovarian cancer, sarcoma, etc | Both monotherapy and synergistic ICBs are available | Effectiveness varies greatly depending on tumor type, drug dose, combination therapy, etc. Both trials with significant clinical benefit and trials with low ORR exist | Nausea, constipation and diarrhea were prominent in AEs. The hematopoietic system such as neutrophils and platelets were susceptible |